Bristol Myers Squibb (BMY) Stock May Be 46% Undervalued After Phase 2 Trial News

Bristol-Myers Squibb has delivered a strong share price run over the past year, which naturally raises a sharper question for anyone looking at the stock today. Is the current price still aligned with what the business can generate in cash terms over time, based on its underlying cash flows?

• The stock is up 44.4% over the past 12 months, which puts more pressure on the cash flow outlook to support the higher valuation investors are now paying.
• Fresh positive Phase 2 data for arlocabtagene autoleucel in relapsed and refractory multiple myeloma can influence expectations for future treatment uptake, potential profitability and the timing of cash inflows if the therapy progresses successfully.
• Prefer to judge Bristol-Myers Squibb on earnings? See what Bristol-Myers Squibb's 14.0x P/E says about the price.

The stock's next move may depend on whether that recent share price performance is fully supported by Bristol-Myers Squibb's current and projected cash flows when measured against an intrinsic value estimate built from its cash generation.

If you want a broader watchlist alongside Bristol-Myers Squibb, a focused screen of 33 high quality undervalued stocks is a straightforward way to find other ideas built on fundamentals.

Does Bristol-Myers Squibb Look Undervalued on Cash Flow?

The Discounted Cash Flow (DCF) model here takes Bristol-Myers Squibb's projected cash generation and discounts it back to today. Latest twelve month free cash flow sits around $11.5b, and the 2 Stage Free Cash Flow to Equity model uses forecasts that keep future annual free cash flows in a similar $10b to $13b range, which assumes a mature business with relatively steady rather than explosive expansion.

That cash profile, when discounted and compared with the current share price of $63.60, results in an estimated intrinsic value that the DCF suggests is substantially above where the stock trades. Positive Phase 2 data for arlocabtagene autoleucel adds another potential contributor to long term cash flows, which helps explain why the cash based valuation sits above the market price. Find out what Bristol-Myers Squibb could be worth using our Discounted Cash Flow (DCF) estimate.

The Bristol-Myers Squibb Narrative: What Would Justify Today's Price?

Simply Wall St Narratives take Bristol-Myers Squibb's valuation puzzle a step further by spelling out which paths for growth, profitability and earnings would need to play out for the stock to look materially richer or cheaper than it does today, and they sit on the platform's Community page. Each one links its number to a clear view on how Bristol-Myers Squibb's growth profile, margins and key risks might evolve, giving you a framework you can revisit as new information emerges.

Bristol-Myers Squibb sparks very different views, with one camp leaning into pipeline and cost gains while the other anchors on the patent cliff and policy pressure.

Bull case: 20% undervalued

"Breakthrough partnerships such as the BioNTech deal position BMS's pipeline for industry leadership in immuno-oncology and radiopharmaceuticals…"

Discover why this Narrative puts Bristol-Myers Squibb at 20% undervalued.

Bear case: 30% overvalued

"The impending loss of exclusivity for major blockbusters such as Eliquis, Opdivo, and Revlimid after 2026 will trigger severe revenue cliffs…"

Explore why this Narrative puts Bristol-Myers Squibb at 30% overvalued.

Before acting on Bristol-Myers Squibb's valuation, there is one more piece to check

Price and cash flows only tell part of the story for Bristol-Myers Squibb, since Simply Wall St's broader checks have also flagged cautionary signals that could influence how you judge the opportunity. Take a closer look at 3 warning signs (1 major) before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com